- Post-Effective Amendment to an S-8 filing (S-8 POS)
April 05 2012 - 4:43PM
Edgar (US Regulatory)
As filed with the Securities and Exchange
Commission on April 5, 2012 Registration No. 333-176664
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO
FORM S-8
REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OF 1933
ARNO THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
200 Route 31 North, Suite 104
|
52-2286452
|
(State or other jurisdiction of
|
Flemington, NJ 08822
|
(I.R.S. Employer
|
Incorporation or organization)
|
Telephone
(862) 703-7170
(Address
of principal executive offices)
|
Identification No.)
|
2005 STOCK OPTION PLAN
(Full
title of the Plan)
Mr. Glenn R. Mattes
|
Copies to:
|
President and Chief Executive Officer
|
Christopher J. Melsha, Esq.
|
Arno Therapeutics, Inc.
|
Sean M. Nagle, Esq.
|
200 Route 31 North, Suite 104
|
Fredrikson & Byron, P.A.
|
Flemington, NJ 08822
|
200 South 6th Street, Suite 4000
|
Telephone: (862) 703-7170
|
Minneapolis, Minnesota 55402
|
(Name and address of agent for service)
|
Telephone: (612) 492-7000
|
|
Facsimile: (612) 492-7077
|
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated
filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
o
|
Accelerated filer
o
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
Smaller reporting company
þ
|
EXPLANATORY NOTE
On September 2, 2011, the Registrant filed
a registration statement on Form S-8 (File No. 333-176664) (the “Registration Statement”). The Registrant
is filing this Post-Effective Amendment No. 1 (“Amendment No. 1”) to the Registration Statement for the sole purpose
of including the consent of Crowe Horwath LLP to permit the incorporation by reference into the Registration Statement of that
firm’s audit report contained in the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2011.
The consent is filed herewith as Exhibit 23.2. Except as otherwise stated herein, no other information contained in the Registration
Statement has been updated by this Amendment No. 1.
PART II
Item 8. Exhibits.
Exhibit
|
|
Description
|
4.1
|
|
Registrant’s 2005 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 10-Q filed August 15, 2011).
|
4.2
|
|
Form of stock option agreement for use under the Registrant’s 2005 Stock Option Plan (incorporated by reference to Exhibit 10.4 of the Registrant’s Form 8-K filed June 9, 2008).
|
4.3
|
|
Amended & Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Registration Statement on Form S-1 filed November 8, 2010, SEC File No. 333-170474).
|
4.4
|
|
Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form SB-2 filed on October 2, 2002, SEC File No. 333-100259).
|
5.1
|
|
Opinion of Fredrikson & Byron, P.A. (previously filed)
|
23.1
|
|
Consent of Crowe Horwath LLP dated September 2, 2011 (previously filed)
|
23.2
|
|
Consent of Crowe Horwath LLP dated April 5, 2012
|
23.3
|
|
Consent of Fredrikson & Byron, P.A. (included in Exhibit 5.1)
|
24.1
|
|
Power of Attorney (previously filed)
|
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Flemington, State of New Jersey, on April 5, 2012.
|
Arno Therapeutics, Inc.
|
|
|
|
|
By:
|
/s/ Glenn R. Mattes
|
|
|
Glenn R. Mattes
|
|
|
President and Chief Executive Officer
|
Pursuant to the requirements of the Securities
Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Glenn R. Mattes
|
|
President, Chief Executive Officer and Director
|
|
April 5, 2012
|
Glenn R. Mattes
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
*
|
|
Treasurer
|
|
April 5, 2012
|
Scott L. Navins
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
*
|
|
Chairman of the Board
|
|
April 5, 2012
|
Arie S. Belldegrun, M.D.
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
April 5, 2012
|
William F. Hamilton, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
|
Tomer Kariv
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
|
Yacov Reizman
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
|
Steven B. Ruchefsky
|
|
|
|
|
|
|
|
|
|
*
|
|
Secretary and Director
|
|
April 5, 2012
|
David M. Tanen
|
|
|
|
|
*
|
/s/ Glenn R. Mattes
|
|
|
Glenn R. Mattes
|
|
|
Attorney-in-fact
|
|
INDEX TO EXHIBITS FILED HEREWITH
Exhibit
|
|
Description
|
23.2
|
|
Consent of Crowe Horwath LLP dated April 5, 2012
|
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024